Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 21.92 -6.80% -1.60
SNDX closed down 6.8 percent on Monday, March 18, 2024, on 1.55 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%

   Recent Intraday Alerts

Alert Time
50 DMA Support about 10 hours ago
Lower Bollinger Band Support about 10 hours ago
Fell Below Lower Bollinger Band about 11 hours ago
Fell Below 50 DMA about 11 hours ago
Down 5% about 11 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Treatment Of Breast Cancer Lung Cancer Cancer Cell Cancer Therapies Hematological Malignancies Pyridines National Cancer Institute Benzamides Histone Deacetylase Inhibitor

Is SNDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.34
52 Week Low 11.23
Average Volume 1,208,082
200-Day Moving Average 18.92
50-Day Moving Average 22.30
20-Day Moving Average 23.40
10-Day Moving Average 23.40
Average True Range 1.23
RSI (14) 44.13
ADX 18.91
+DI 16.06
-DI 17.88
Chandelier Exit (Long, 3 ATRs) 21.66
Chandelier Exit (Short, 3 ATRs) 25.55
Upper Bollinger Bands 24.77
Lower Bollinger Band 22.04
Percent B (%b) -0.04
BandWidth 11.69
MACD Line 0.26
MACD Signal Line 0.49
MACD Histogram -0.2251
Fundamentals Value
Market Cap 1.86 Billion
Num Shares 84.8 Million
EPS -2.59
Price-to-Earnings (P/E) Ratio -8.46
Price-to-Sales 12.67
Price-to-Book 5.22
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.43
Resistance 3 (R3) 24.69 24.12 24.01
Resistance 2 (R2) 24.12 23.48 23.99 23.87
Resistance 1 (R1) 23.02 23.09 22.74 22.76 23.73
Pivot Point 22.45 22.45 22.31 22.32 22.45
Support 1 (S1) 21.35 21.81 21.07 21.09 20.11
Support 2 (S2) 20.78 21.42 20.65 19.97
Support 3 (S3) 19.68 20.78 19.83
Support 4 (S4) 19.42